Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Emerg Drugs. 2012 Dec;17(4):439-44. doi: 10.1517/14728214.2012.720252. Epub 2012 Sep 21.

Reinventing primaquine for endemic malaria.

Abstract

After sixty years of continuous use, primaquine remains the only therapy licensed for arresting transmission and relapse of malaria. The US Army developed primaquine for soldiers in a wartime crisis setting. Dosing strategies suited to that narrow population were adopted without modification or validation for the broader population of humans exposed to risk of malaria. The poor suitability of these strategies in populations exhibiting greater vulnerability to hemolytic toxicity among glucose-6-phosphate dehydrogenase deficient patients has not been addressed. Primaquine requires chemotherapeutic reinvention delivering less threatening doses by leveraging unexplored co-drug synergies.

PMID:
22998791
PMCID:
PMC3514001
DOI:
10.1517/14728214.2012.720252
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center